CHICAGO, November 13, 2024 —  Vyaire Medical today announced that it has completed the sale of the Vyaire Respiratory Diagnostics (RDx) Business Unit and its products to Trudell Medical Limited. 

“The sale allows the RDx Business Unit to move forward with a mandate to continue to serve our customers and patients with industry-leading respiratory diagnostics,” said Will Throp, CEO, RDx. “Trudell Medical has been an outstanding partner for Vyaire RDx in Canada and has clearly aligned values, making it a great fit for our team and products.”  

The Trudell Medical Group of companies has been in operation for over 100 years. They deliver innovative medical devices and services to patients and healthcare professionals in over 110 countries. Under the terms of the agreement, Trudell Medical acquired the RDx product portfolio and existing inventory, along with associated consumables, service parts, accessories, and service program offerings.

Throp added, “Vyaire and Trudell Medical will work together closely to ensure a smooth transition for our team members, customers, and partners.”

The sale to Trudell Medical follows the sale of the Vyaire Ventilation Business Unit to ZOLL Medical Corporation. Following the sale of the RDx Business Unit, the Vyaire Medical estate will be wound down as part of the Chapter 11 bankruptcy process.

_________________________________

About Vyaire Medical

Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 70-year history of pioneering breathing technology, the integrated solutions offered by the company’s Ventilation and Respiratory Diagnostics (RDx) businesses help enable, enhance, and extend lives. Vyaire products are available in more than 100 countries and are recognized, trusted, and preferred by specialists throughout the respiratory community worldwide.